SCHEMBL6717161

SCHEMBL6717161

Cc1ccc(NC(=O)N(S)C(C(=O)Nc2c(C)cccc2C)c2ccccc2)c([N+](=O)[O-])c1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
MAPT P10636 3/20 0.53
POLB P06746 1/20 0.48
KDM4E B2RXH2 1/20 0.47
LMNA P02545 1/20 0.47
MAPK1 P28482 1/20 0.47
KCNMA1 Q12791 2/20 0.45
NPC1 O15118 5/20 0.45
RAB9A P51151 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TRPV1 Q8NER1 1/20 0.40
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6713799 0.90 KMT2A (0.49) ALDH1A1MAPTPOLBLMNAMAPK1
SCHEMBL6715694 0.89 RAB9A (0.52) ALDH1A1MAPTPOLBLMNAMAPK1
SCHEMBL6716685 0.87 MAPT (0.52) ALDH1A1MAPTPOLBLMNAMAPK1
SCHEMBL6723757 0.83 MAPT (0.48) ALDH1A1MAPTPOLBLMNAMAPK1
SCHEMBL6723841 0.83 MAPT (0.52) ALDH1A1MAPTPOLBLMNAMAPK1
SCHEMBL6717235 0.83 MEN1 (0.53) ALDH1A1MAPTPOLBLMNANPC1
SCHEMBL6717674 0.83 RAB9A (0.47) ALDH1A1MAPTPOLBLMNAMAPK1
SCHEMBL6713814 0.83 KMT2A (0.49) ALDH1A1MAPTPOLBLMNAMAPK1
SCHEMBL6716840 0.83 KMT2A (0.49) ALDH1A1MAPTPOLBLMNAMAPK1
SCHEMBL6719452 0.83 MAPT (0.51) ALDH1A1MAPTPOLBLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 ALDH1A1 572/4885MAPT 427/4885POLB 4182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.